748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

• Daniel Olson,
• Manish Sharma,
• Erminia Massarelli,
• Jonathan Thompson,
• Rachel E Sanborn,
• Ralph J Hauke,
• Anthony W Tolcher,
• Elizabeth Davis,
• Conor Steuer,
• Muhammad Furqan,
• John Hamm,
• Doug Laux,
• David Berz,
• Wade T Iams,
• Vasily Andrianov,
• Brianne O’Neill,
• Yaiza Diaz De Durana

Affiliations

Daniel Olson

4University of Chicago Comprehensive Cancer Center, Chicago, IL, USA

Manish Sharma

3START Midwest, Grand Rapids, MI, USA

Erminia Massarelli

7City of Hope, Duarte, CA, USA

Jonathan Thompson

10Medical College of Wisconsin, Milwaukee, WI, USA

Rachel E Sanborn

1Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA

Ralph J Hauke

6Nebraska Cancer Specialists, Omaha, NE, USA

Anthony W Tolcher

13NEXT Oncology, San Antonio, TX, USA

Elizabeth Davis

9Vanderbilt University Medical Center, Nashville, TN, USA

Conor Steuer

8Winship Cancer Institute of Emory University, Atlanta, GA, USA

Muhammad Furqan

2University of Iowa, Carver College of Medicine, Iowa City, IA, USA

John Hamm

11Norton Healthcare, Louisville, KY, USA

Doug Laux

2University of Iowa, Carver College of Medicine, Iowa City, IA, USA

David Berz

5Valkyrie Clinical Trials, Los Angeles, CA, USA

Wade T Iams

9Vanderbilt University Medical Center, Nashville, TN, USA

Vasily Andrianov

12Inhibrx, Inc, La Jolla, CA, USA

Brianne O’Neill

12Inhibrx, Inc, La Jolla, CA, USA

Yaiza Diaz De Durana

12Inhibrx, Inc, La Jolla, CA, USA